---
title: "China Resources Pharmaceutical's subsidiary KPC earned 350 million RMB last year, a decline of 46%"
description: "China Resources Pharmaceutical announced that its subsidiary KPC's preliminary performance for the year 2025 is expected to show a total operating revenue of 6.577 billion RMB, a year-on-year decrease"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275223953.md"
published_at: "2026-02-08T10:01:36.000Z"
---

# China Resources Pharmaceutical's subsidiary KPC earned 350 million RMB last year, a decline of 46%

> China Resources Pharmaceutical announced that its subsidiary KPC's preliminary performance for the year 2025 is expected to show a total operating revenue of 6.577 billion RMB, a year-on-year decrease of 21.7%, due to a decline in both the sales scale and gross profit margin of the group's products. The net profit attributable to shareholders is expected to be 350 million RMB, a decline of 46%

China Resources Pharmaceutical (03320.HK) announced the preliminary performance of its subsidiary KPC (600422.SH) for the fiscal year 2025. Due to a decline in both the sales scale and gross profit margin of the group's products compared to the same period last year, the total operating revenue is expected to be RMB 6.577 billion, a year-on-year decrease of 21.7%. The net profit attributable to shareholders is expected to be RMB 350 million, a decline of 46%

### Related Stocks

- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [513060.CN - Bosera Hang Seng Health Care ETF(QDII)](https://longbridge.com/en/quote/513060.CN.md)
- [03320.HK - CHINARES PHARMA](https://longbridge.com/en/quote/03320.HK.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| KPC Pharmaceutical's 2025 Profit Slips 46% | KPC Pharmaceutical's 2025 Profit Slips 46% | [Link](https://longbridge.com/en/news/275129339.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.